The effects of a cysteinyl leukotriene receptor antagonist, pranlukast, on dendritic cell chemoattractants in the airways of subjects with asthma Source: Eur Respir J 2004; 24: Suppl. 48, 132s Year: 2004
The CysLT1 receptor antagonist montelukast inhibits mast cell activation induced by inhaled leukotriene E4 in subjects with asthma Source: International Congress 2016 – Clinical and molecular studies in asthma Year: 2016
Cysteinyl leukotriene receptor antagonist regulates vascular permeability by reducing VEGF expression Source: Eur Respir J 2004; 24: Suppl. 48, 129s Year: 2004
The pro-apoptotic effect of cysteinyl leukotriene receptor (CysLT-R) antagonist montelukast is mediated by CysLT-Rs expression on antigen-stimulated T cells Source: Eur Respir J 2003; 22: Suppl. 45, 100s Year: 2003
Effect of cysteinyl leukotriene receptor antagonist on airway wall remodeling Source: Eur Respir J 2002; 20: Suppl. 38, 304s Year: 2002
Expression of the cysteinyl leukotriene receptors cysLT1 and cysLT2 in the airway structural cells Source: Eur Respir J 2005; 26: Suppl. 49, 346s Year: 2005
Inhibition of LPS-induced neutrophil recruitment in the lungs correlates with modulation of neutrophil CD11b expression using the selective CXCR2 receptor antagonist SB-656933 Source: Eur Respir J 2004; 24: Suppl. 48, 218s Year: 2004
Upregulation of cysteinyl leukotriene receptors CysLT1 and CysLT2 by TGF-β1 and LTE4 on human bronchial epithelial cells Source: Annual Congress 2006 - Airway epithelial cells in inflammation Year: 2006
Interactive inhibitory effects of formoterol and montelukast on activated human neutrophils Source: Eur Respir J 2010; 36: 1417-1424 Year: 2010
Quantitative assessment of cysteinyl leukotrienes in human sputum during the allergen-induced asthmatic response and the effect of GSK2190915, a 5-lipoxygenase activating protein (FLAP) inhibitor Source: Annual Congress 2011 - Diagnosis and treatment of inflammatory respiratory diseases Year: 2011
Protective effect of cysteinyl leukotriene receptor antagonist montelukast in bleomycin induced pulmonary fibrosis Source: Eur Respir J 2007; 30: Suppl. 51, 111s Year: 2007
The CysLT1 receptor antagonist montelukast blocks bronchoconstriction induced by inhaled leukotriene E4 in subjects with asthma Source: International Congress 2015 – The immunology of allergic airway disease Year: 2015
Effects of leukotriene receptor antagonists on airway mucus secretion Source: Eur Respir J 2001; 18: Suppl. 33, 245s Year: 2001
Leukotriene C4 synthase polymorphism does not associate with clinical response to leukotriene receptor antagonists in persistent asthma Source: Eur Respir J 2002; 20: Suppl. 38, 303s Year: 2002
The selective CXCR2 receptor antagonist SB-656933 inhibits CXCL1-induced neutrophil CD11b expression in human whole blood Source: Eur Respir J 2004; 24: Suppl. 48, 218s Year: 2004
Effect of thromboxane A2 (TXA2 ) synthase inhibitor and TXA2 receptor antagonist alone and in combination on antigen-induced bronchoconstriction in guinea pigs Source: Eur Respir J 2001; 18: Suppl. 33, 264s Year: 2001
Intranasal administration of leukotriene B4 selectively increases human nasal neutrophil activity Source: Annual Congress 2008 - Phenotyping of asthma and COPD Year: 2008
Increased expression of the cysteinil leukotriene 1 receptor (CysLT1-R) in the bronchial epithelium of smokers Source: Eur Respir J 2001; 18: Suppl. 33, 74s Year: 2001
Muscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 20s Year: 2004
Fevipiprant inhibits eosinophil activation induced by multiple metabolites of prostaglandin D2 Source: International Congress 2019 – COPD, asthma and rhinitis: from cellular mechanisms to patients’ clinical responses Year: 2019